INMB INmune Bio Inc.

4.94
-0.06  -1%
Previous Close 5
Open 5.03
Price To Book 2.15
Market Cap 53,157,860
Shares 10,770,948
Volume 3,286
Short Ratio
Av. Daily Volume 20,290
Stock charts supplied by TradingView

NewsSee all news

  1. INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals

    LA JOLLA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), an immunology company developing treatments that harness the patient's innate immune system to fight disease, announced today the

  2. INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials

    Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer LA JOLLA, Calif. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing therapies that reprogram the

  3. INmune Bio, Inc. Announces First Alzheimer's Disease Patient Dosed in XPro1595 Study

    Neuroinflammation targeted in XPro1595 Phase Ib clinical trial LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB), an immunology company developing treatments that

  4. INmune Bio Inc. to Discuss Potential New Alzheimer's Disease Treatments in CTAD Pre-Conference Webinar

    INmune Bio's CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer's drug development. LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- -- INmune

  5. INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen

    LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB), an immunology company developing treatments that harness the patient's innate immune system to fight disease, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated.
INB03
HER2+ breast cancer
Phase 1b initiation of dosing announced December 2, 2019 with data due 2H 2020.
XPro1595
Alzheimer’s disease

Latest News

  1. INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals

    LA JOLLA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), an immunology company developing treatments that harness the patient's innate immune system to fight disease, announced today the

  2. INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials

    Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer LA JOLLA, Calif. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing therapies that reprogram the

  3. INmune Bio, Inc. Announces First Alzheimer's Disease Patient Dosed in XPro1595 Study

    Neuroinflammation targeted in XPro1595 Phase Ib clinical trial LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB), an immunology company developing treatments that

  4. INmune Bio Inc. to Discuss Potential New Alzheimer's Disease Treatments in CTAD Pre-Conference Webinar

    INmune Bio's CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer's drug development. LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- -- INmune

  5. INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen

    LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:INMB), an immunology company developing treatments that harness the patient's innate immune system to fight disease, today announced that

  6. INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update

    LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), an immunology company developing treatments that harness the patient's innate immune system to fight disease, today

  7. INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting

    Dr. Malú Tansey's new data highlighted at today's press conference LA JOLLA, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), an immunology company developing treatments that harness the

  8. INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October

    LA JOLLA, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced

  9. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  10. NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) CEO Discusses Company Achievements in Interview; Director of Neuroscience to Present at World Immunotherapy Congress

    RJ Tesi, M.D., co-founder and CEO of clinical-stage immunology company INmune Bio (NASDAQ:INMB), was recently featured in an interview with multimedia financial reporter Jason Lin. Among other highlights, Dr. Tesi

  11. CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq's MarketSite and Announces Presentation at World Immunotherapy Congress

    La Jolla, CA., Sept. 24, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today

  12. NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present XPro1595 for Treating Neuroinflammation in Alzheimer's Disease at 2019 AAIC Satellite Symposium

    INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced its plans to present at the upcoming

  13. INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer's Disease at 2019 Alzheimer's Association International Conference (AAIC) Satellite Symposium

    LA JOLLA, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), an immunotherapy company developing treatments which harness the patient's innate immune system to fight disease, announced today

  14. INmune Bio Invited to Speak on Company's Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress

    La Jolla, CA., Sept. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced

  15. INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer

    LA JOLLA, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage immunology company focused on developing treatments that reprogram the patient's innate immune system to fight